Announcement • Jun 19
Oncoinvent Achieves 50% Recruitment Milestone in Phase 2 Ovarian Cancer Study of Radspherin Oncoinvent announced that its ongoing Phase 2 trial of Radspherin in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone. A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has accelerated significantly in 2026, with 11 patients enrolled in the first quarter and 17 patients recruited in the second quarter to date, marking the high recruitment levels achieved in the study so far. Year-to-date recruitment of 28 patients has already surpassed total enrollment for 2025. Four new sites have opened for recruitment in 2026 and in total ten hospitals across the United States, Spain, Norway, Belgium, the United Kingdom and Italy are currently active in the trial, and further site activations are ongoing to support continued recruitment. The Phase 2 trial (ClinicalTrials.gov: NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival between patients receiving Radspherin following complete surgical resection and pre-operative chemotherapy, and those receiving standard of care treatment consisting of chemotherapy and surgery alone. Previous Phase 1 and Phase 1/2a data have demonstrated that Radspherin is well tolerated, with no dose-limiting toxicity observed at the recommended dose of 7MBq, and encouraging signals of efficacy. Results from the Phase 1 study in ovarian cancer have been published in the peer-reviewed journal Gynecologic Oncology, and results from the Phase 1/2a study in colorectal cancer have been published in the peer-reviewed journals Journal of Surgical Oncology and Frontiers in Medicine. Reported Earnings • Apr 24
Full year 2025 earnings released: kr1.25 loss per share (vs kr152 loss in FY 2024) Full year 2025 results: kr1.25 loss per share. Revenue: kr28.1m (up 246% from FY 2024). Net loss: kr155.1m (loss widened 11% from FY 2024). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Pharmaceuticals industry in Europe. Announcement • Mar 20
Oncoinvent Secures New Patent Expanding Protection for Radspherin Oncoinvent announced that the China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin®, the Company's lead product candidate, marking the first approval worldwide within this patent family. The newly granted patent covers a key technical development to optimize Radspherin's® performance, specifically the size-controlled calcium carbonate microparticle technology. With this grant, patent protection for Radspherin® in China is expanded in scope and duration, with a term extending to 2041. This complements the existing composition-of-matter patent, which is valid until 2035 (2036 in some jurisdictions). Corresponding patent applications from the same patent family remain under review in several major jurisdictions worldwide. New Risk • Mar 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 12% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (kr164m net loss in 3 years). Revenue is less than US$5m (kr20m revenue, or US$2.0m). Market cap is less than US$100m (kr199.7m market cap, or US$20.4m). Announcement • Feb 18
Oncoinvent to Present Positive 24-Month Follow-Up Data from Phase 1 Ovarian Cancer Study of Radspherin at ESGO 2026 Oncoinvent announced that it will present final 24-month results from its RAD-18-001 Phase 1 study of Radspherin after cytoreductive surgery in patients with platinum-sensitive epithelial ovarian cancer and peritoneal recurrence at the European Society of Gynaecological Oncology (ESGO) 2026 Congress, taking place in Copenhagen, Denmark, from 26-28 February 2026. Radspherin is an intraperitoneal alpha-emitting therapy (224Ra-labeled microparticles), targeting remaining cancer cells while sparing healthy tissue within the peritoneal cavity to address microscopic residual disease following cytoreductive surgery, to prevent recurrence and enhance long-term patient outcomes. The poster presentation, titled 'Safety and efficacy results from a phase 1 study of intraperitoneal alpha-EMitting radium-224 labelled microparticles after cytoreductive surgery, will share final 24-month data from the Phase 1 study detailing: 21 patients enrolled across dose levels with a favourable safety profile and no dose-limiting toxicities observed; No grade 3 adverse events considered related to Radspherin; Recommended dose selected at 7 MBq following dose escalation; Durable local disease control signal at 24 months: only 1 of 10 patients treated at the recommended dose experienced peritoneal recurrence. Announcement • Jan 13
Oncoinvent ASA Announces Appointment of Ramzi Amri as CEO, Effective January 2026 Oncoinvent ASA announced the appointment of Ramzi Amri as the new CEO of the Company as of January 2026. New Risk • Dec 11
New major risk - Revenue and earnings growth Earnings have declined by 18% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Revenue is less than US$5m (kr20m revenue, or US$2.0m). Market cap is less than US$100m (kr257.5m market cap, or US$25.5m). Recent Insider Transactions Derivative • Dec 03
Chair of the Board exercised options to buy kr371k worth of stock. On the 27th of November, Charles O'Bryan-Tear exercised options to buy 699k shares at a strike price of around kr0.50, costing a total of kr349k. This transaction amounted to 48% of their direct individual holding at the time of the trade. Since December 2024, Charles' direct individual holding has increased from 350.00k shares to 2.17m. Company insiders have collectively bought kr402k more than they sold, via options and on-market transactions, in the last 12 months. Announcement • Dec 03
Oncoinvent ASA has completed a Follow-on Equity Offering in the amount of NOK 130 million. Oncoinvent ASA has completed a Follow-on Equity Offering in the amount of NOK 130 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 260,000,000
Price\Range: NOK 0.5
Transaction Features: Rights Offering Board Change • Nov 03
No independent directors There are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 3 experienced directors. No highly experienced directors. No independent directors (7 non-independent directors). Director Orlando Oliveira is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Announcement • Nov 01
Oncoinvent ASA Announces CFO Changes, Effective on or Around January 15, 2025 Oncoinvent ASA announced the appointment of Dr. Ramzi Amri, M.D., Ph.D. as Chief Financial Officer (CFO), effective on or around 15 January. Dr. Amri succeeds Tore Kvam, who has served as CFO since 2019. Dr. Amri joins Oncoinvent from Galapagos NV, where he most recently served as Vice President and Head of Development Strategy & Execution. He brings broad international experience through leadership positions in strategy, operations, and corporate transformation across the life sciences and healthcare industries. Dr. Amri also brings seven years of management consulting experience from McKinsey & Company, advising global pharma and biotech clients, as well as financial institutions and private-equity-backed businesses, on growth, M&A, and organizational transformation. Dr. Amri holds an M.D. and a Ph.D. from the University of Amsterdam. He conducted his Ph.D. research and completed a postdoctoral fellowship in surgical oncology and epidemiology at Harvard Medical School and Massachusetts General Hospital, where he initiated and led a research program in colorectal cancer. 
